Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ('Calliditas'), a commercial biopharma company focused on rare diseases today announced that Maria Tornsen has been appointed to the position of President North America.

Ms Tornsen will be responsible for all US based operations and will report to the CEO.

Maria Tornsen has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles. Most recently Ms Tornsen held the position of Chief Commercial Officer at Passage Bio, prior to which she was SVP General Manager US at Sarepta Therapeutics. Prior to joining Sarepta she served as VP Global Therapeutic Area Head at Sanofi Genzyme and held several senior commercial roles at Shire including VP Head of US Sales. Ms Tornsen will replace Mr Andrew Udell, who has held the position since 2020.

'We are pleased to welcome Ms Tornsen to the executive management team as President of our US operations. She brings invaluable experience from building commercial organisations, driving growth and profitability in the area of rare diseases, which will be critical as we target the next step in our development.' said CEO Renee Aguiar-Lucander. 'I also want to thank Mr Udell for his valuable contribution to the build-up of the US organisation and its early commercial success.'

'I am delighted to join Calliditas at this exciting time in the company's history, with the recent full FDA approval of TARPEYO and an innovative late-stage pipeline in rare diseases. I look forward to working with the Calliditas team to continue advancing the TARPEYO launch and develop our capabilities to support further growth.' said Maria Tornsen.

Calliditas received full FDA approval of TARPEYO(budesonide) delayed release capsules, a targeted treatment to reduce the loss of kidney function in patients with primary IgA nephropathy (IgAN) at risk of disease progression on December 20, 2023; the product has been granted conditional approval in Europe and China and is being commercialized by partners under the brand names of Kinpeygo and Nefecon, respectively. Calliditas is targeting top line read out of several Phase 2 clinical trials with setanaxib, its lead product candidate from its proprietary and novel NOX platform, in 2024.

Contact:

Asa Hillsten

Tel: +46 76 403 35 43

Email: asa.hillsten@calliditas.com

About Calliditas

Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the development of Calliditas' pipeline. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Calliditas' business, operations, clinical trials, intellectual property of the NEFECON franchise globally, competition from other companies, pipeline development, revenue and product sales projections or forecasts and other risks identified in the section entitled 'Risk Factors' in Calliditas' reports filed with the Securities and Exchange Commission. Calliditas cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Calliditas disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Calliditas' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Contact:

Tel: +1 844-442-0011

Email: medical.information@calliditas.com

(C) 2024 Electronic News Publishing, source ENP Newswire